These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 7585062)

  • 1. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression.
    Koenig S; Conley AJ; Brewah YA; Jones GM; Leath S; Boots LJ; Davey V; Pantaleo G; Demarest JF; Carter C
    Nat Med; 1995 Apr; 1(4):330-6. PubMed ID: 7585062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A long-term follow-up of an HIV type 1-infected patient reveals a coincidence of Nef-directed cytotoxic T lymphocyte effectors and high incidence of epitope-deleted variants.
    Singh MK; Janvier G; Calvez V; Coulaud P; Rivière Y
    AIDS Res Hum Retroviruses; 2001 Sep; 17(13):1265-71. PubMed ID: 11559426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Course of specific T lymphocyte cytotoxicity, plasma and cellular viral loads, and neutralizing antibody titers in 17 recently seroconverted HIV type 1-infected patients.
    Legrand E; Pellegrin I; Neau D; Pellegrin JL; Ragnaud JM; Dupon M; Guillemain B; Fleury HJ
    AIDS Res Hum Retroviruses; 1997 Nov; 13(16):1383-94. PubMed ID: 9359658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of HIV-1 Nef vaccine components: immunogenicity study of Nef mutants lacking myristoylation and dileucine motif in mice.
    Liang X; Fu TM; Xie H; Emini EA; Shiver JW
    Vaccine; 2002 Sep; 20(27-28):3413-21. PubMed ID: 12213412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo.
    Haas G; Plikat U; Debré P; Lucchiari M; Katlama C; Dudoit Y; Bonduelle O; Bauer M; Ihlenfeldt HG; Jung G; Maier B; Meyerhans A; Autran B
    J Immunol; 1996 Nov; 157(9):4212-21. PubMed ID: 8892659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients.
    Lieberman J; Skolnik PR; Parkerson GR; Fabry JA; Landry B; Bethel J; Kagan J
    Blood; 1997 Sep; 90(6):2196-206. PubMed ID: 9310470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells transfected with the nef genes of HIV-1 primary isolates specifically activate cytotoxic T lymphocytes from seropositive subjects.
    Chassin D; Andrieu M; Cohen W; Culmann-Penciolelli B; Ostankovitch M; Hanau D; Guillet JG
    Eur J Immunol; 1999 Jan; 29(1):196-202. PubMed ID: 9933101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD8(+)-Cell antiviral factor activity is not restricted to human immunodeficiency virus (HIV)-specific T cells and can block HIV replication after initiation of reverse transcription.
    Le Borgne S; Février M; Callebaut C; Lee SP; Rivière Y
    J Virol; 2000 May; 74(10):4456-64. PubMed ID: 10775581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.
    Harrer E; Bäuerle M; Ferstl B; Chaplin P; Petzold B; Mateo L; Handley A; Tzatzaris M; Vollmar J; Bergmann S; Rittmaier M; Eismann K; Müller S; Kalden JR; Spriewald B; Willbold D; Harrer T
    Antivir Ther; 2005; 10(2):285-300. PubMed ID: 15865223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.
    van Baalen CA; Pontesilli O; Huisman RC; Geretti AM; Klein MR; de Wolf F; Miedema F; Gruters RA; Osterhaus AD
    J Gen Virol; 1997 Aug; 78 ( Pt 8)():1913-8. PubMed ID: 9266987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of cytotoxic T-lymphocyte-mediated immune selection in a dominant human leukocyte antigen-B8-restricted cytotoxic T-lymphocyte epitope in Nef.
    Maurer K; Harrer EG; Goldwich A; Eismann K; Bergmann S; Schmitt-Haendle M; Spriewald B; Mueller SM; Harrer T;
    J Acquir Immune Defic Syndr; 2008 Jun; 48(2):133-41. PubMed ID: 18391752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive screening for human immunodeficiency virus type 1 subtype-specific CD8 cytotoxic T lymphocytes and definition of degenerate epitopes restricted by HLA-A0207 and -C(W)0304 alleles.
    Currier JR; deSouza M; Chanbancherd P; Bernstein W; Birx DL; Cox JH
    J Virol; 2002 May; 76(10):4971-86. PubMed ID: 11967314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.
    Collins KL; Chen BK; Kalams SA; Walker BD; Baltimore D
    Nature; 1998 Jan; 391(6665):397-401. PubMed ID: 9450757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid HIV disease progression following superinfection in an HLA-B*27:05/B*57:01-positive transmission recipient.
    Brener J; Gall A; Hurst J; Batorsky R; Lavandier N; Chen F; Edwards A; Bolton C; Dsouza R; Allen T; Pybus OG; Kellam P; Matthews PC; Goulder PJR
    Retrovirology; 2018 Jan; 15(1):7. PubMed ID: 29338738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different effects of Nef-mediated HLA class I down-regulation on human immunodeficiency virus type 1-specific CD8(+) T-cell cytolytic activity and cytokine production.
    Tomiyama H; Akari H; Adachi A; Takiguchi M
    J Virol; 2002 Aug; 76(15):7535-43. PubMed ID: 12097566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conservation of cytotoxic T lymphocyte (CTL) epitopes as a host strategy to constrain parasite adaptation: evidence from the nef gene of human immunodeficiency virus 1 (HIV-1).
    da Silva J; Hughes AL
    Mol Biol Evol; 1998 Oct; 15(10):1259-68. PubMed ID: 9787432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus.
    Kumar A; Mukherjee S; Shen J; Buch S; Li Z; Adany I; Liu Z; Zhuge W; Piatak M; Lifson J; McClure H; Narayan O
    Virology; 2002 Sep; 301(2):189-205. PubMed ID: 12359422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals.
    Reiss P; de Wolf F; Kuiken CL; de Ronde A; Dekker J; Boucher CA; Debouck C; Lange JM; Goudsmit J
    J Acquir Immune Defic Syndr (1988); 1991; 4(2):165-72. PubMed ID: 1898969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenic region of the human immunodeficiency virus 1 NEF protein.
    Couillin I; Culmann-Penciolelli B; Gomard E; Choppin J; Levy JP; Guillet JG; Saragosti S
    J Exp Med; 1994 Sep; 180(3):1129-34. PubMed ID: 7520468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: evidence for impaired CTL effector function.
    Kostense S; Ogg GS; Manting EH; Gillespie G; Joling J; Vandenberghe K; Veenhof EZ; van Baarle D; Jurriaans S; Klein MR; Miedema F
    Eur J Immunol; 2001 Mar; 31(3):677-86. PubMed ID: 11241270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.